Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with ...
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer
Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and ...
Nasdaq27d
Redburn Atlantic Initiates Coverage of Lantheus Holdings (LNTH) with Buy Recommendation
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of ...
ascopubs.org19d
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non–Small Cell Lung Cancer Surpasses 5 years Patients with recurrent T1 bladders ...
Wall Street Journal3d
Bausch Health Cos. Inc.
$ 8.02 0.00 0.00% ...